Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Public ClinicalTrials.gov record NCT03118843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to determine the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection with or without cirrhosis, who did not achieve sustained viral response (SVR) after receiving prior treatment in a Gilead-sponsored HCV treatment study of direct-acting antiviral (DAA)-containing regimens.
Study identification
- NCT ID
- NCT03118843
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2017 (Actual)
- Primary completion
- Mar 19, 2018 (Actual)
- Completion
- Mar 19, 2018 (Actual)
- Last update posted
- Apr 3, 2019
2017 – 2018
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ruane Clinical Research Group Inc. | Los Angeles | California | 90036 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Stanford Hospital and Clinics | Palo Alto | California | 94304 | — |
| Inland Empire Liver Foundation | Rialto | California | 92377 | — |
| Kaiser Permanente | San Diego | California | 92154 | — |
| University of Colorado Denver (Leprino Building) | Aurora | Colorado | 80045 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Emory Hospital Midtown Infectious Disease Clinic | Atlanta | Georgia | 30308 | — |
| Gastrointestinal Specialists of Georgia | Marietta | Georgia | 30060 | — |
| Saint Louis University, Gastroenterology & Hepatology, Clinical Research Unit | St Louis | Missouri | 63104 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| Columbia University Medical Center/ New York Presbyterian | New York | New York | 10032 | — |
| Center for Liver Diseases, Oakland | Pittsburgh | Pennsylvania | 15213 | — |
| University Gastroenterology | Providence | Rhode Island | 02905 | — |
| Gastro One | Germantown | Tennessee | 38138 | — |
| New Orleans Center for Clinical Research | Knoxville | Tennessee | 37920 | — |
| University of Washington/Harborview Medical Center | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03118843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2019 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03118843 live on ClinicalTrials.gov.